MCIM
TBPH icon

Meadow Creek Investment Management’s Theravance Biopharma TBPH Stock Holding History

Meadow Creek Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Buy
1,152
+800
+227% +$16.2K ﹤0.01% 1316
2019
Q2 		$6K Hold
352
– – ﹤0.01% 1347
2019
Q1 		$8K Hold
352
– – ﹤0.01% 1337
2018
Q4 		$9K Buy
+352
New +$9.5K ﹤0.01% 1304

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meadow Creek Investment Management's TBPH Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Theravance Biopharma (TBPH) stake by 227% in Q3 2019, buying an estimated $16.2K and bringing the position to 1,152 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

Meadow Creek Investment Management first reported a position in TBPH in Q4 2018 and has held it in 4 quarters since. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

  • Meadow Creek Investment Management held 1,152 shares of Theravance Biopharma worth $22K as of Q3 2019.
  • Meadow Creek Investment Management bought 800 Theravance Biopharma shares in Q3 2019, an estimated $16.2K.
  • Theravance Biopharma made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1316 holding.
  • Meadow Creek Investment Management first reported a position in Theravance Biopharma in Q4 2018 and has held it in 4 quarters since.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.